Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene.
Ontology highlight
ABSTRACT: Current HIV-1 gene therapy approaches aim at stopping the viral life cycle at its earliest steps, such as entry or immediate postentry events. Among the most widely adopted strategies are CCR5 downregulation/knockout and the use of broadly neutralizing antibodies. However, the long-term efficacy and side effects are still unclear. TRIM5α is an interferon-stimulated restriction factor that can intercept incoming retroviruses within one hour of cytosolic entry and potently inhibit the infectivity of restriction-sensitive viruses. The human TRIM5α (TRIM5αhu) generally does not efficiently target HIV-1, but point mutations in its capsid-binding domain can confer anti-HIV-1 activity. Although the mechanisms by which TRIM5αhu mutants inhibit HIV-1 are relatively well understood, their characteri
SUBMITTER: Jung U
PROVIDER: S-EPMC4630796 | biostudies-literature | 2015 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA